Jiangsu Nhwa Pharmaceutical Co., LTD

XSEC:002262 Stock Report

Market Cap: CN¥22.9b

Jiangsu Nhwa Pharmaceutical Past Earnings Performance

Past criteria checks 4/6

Jiangsu Nhwa Pharmaceutical has been growing earnings at an average annual rate of 11.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 8.4% per year. Jiangsu Nhwa Pharmaceutical's return on equity is 16.4%, and it has net margins of 21.2%.

Key information

11.9%

Earnings growth rate

11.8%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate8.4%
Return on equity16.4%
Net Margin21.2%
Next Earnings Update29 Mar 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Jiangsu Nhwa Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:002262 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 245,5311,1712,139600
30 Jun 245,4051,1212,027613
31 Mar 245,2201,0751,979583
31 Dec 235,0421,0371,959549
30 Sep 234,8341,0441,885548
30 Jun 234,6989981,943501
31 Mar 234,4859391,910463
01 Jan 234,2999011,849454
30 Sep 224,1648671,847408
30 Jun 224,0728341,810387
31 Mar 224,0248191,743385
01 Jan 223,9367981,750352
30 Sep 213,8798301,638308
30 Jun 213,7447871,587301
31 Mar 213,5287591,516277
31 Dec 203,3617291,445246
30 Sep 203,3267141,435236
30 Jun 203,5346941,498214
31 Mar 203,8376751,622185
31 Dec 194,1496631,664189
30 Sep 194,1676231,608182
30 Jun 194,0905851,512181
31 Mar 193,9815491,421178
31 Dec 183,8585251,350172
30 Sep 183,7644721,173149
30 Jun 183,5814471,077179
31 Mar 183,4824111,082146
31 Dec 173,3943951,066111
30 Sep 173,2744001,12179
30 Jun 173,1813471,1640
31 Mar 173,0973251,0850
31 Dec 163,0183101,0050
30 Sep 163,0042979630
30 Jun 162,9372848800
31 Mar 162,8512698560
31 Dec 152,7672588170
30 Sep 152,6942577600
30 Jun 152,6282467450
31 Mar 152,5662357180
31 Dec 142,5012236920
30 Sep 142,4182136760
30 Jun 142,3752016750
31 Mar 142,3101866770

Quality Earnings: 002262 has high quality earnings.

Growing Profit Margin: 002262's current net profit margins (21.2%) are lower than last year (21.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 002262's earnings have grown by 11.9% per year over the past 5 years.

Accelerating Growth: 002262's earnings growth over the past year (12.2%) exceeds its 5-year average (11.9% per year).

Earnings vs Industry: 002262 earnings growth over the past year (12.2%) exceeded the Pharmaceuticals industry -2.5%.

Return on Equity

High ROE: 002262's Return on Equity (16.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/11 12:10
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jiangsu Nhwa Pharmaceutical Co., LTD is covered by 24 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
Yanyin ZhuChina International Capital Corporation Limited
Shanshan LiChina Merchants Securities Co. Ltd.